ASX Health Stocks: Cann to market over-the-counter CBD capsules in Australia
Health & Biotech
Health & Biotech
Link copied to
Cannabis company Cann Group (ASX:CAN) has entered into an exclusive deal with GSK Consumer Healthcare to commercialise Cann’s Satipharm CBD capsules.
The capsules will be sold over-the-counter (OTC) in Australia (S3 registration status), and potentially other markets globally.
During the period of exclusivity, GSK Consumer Healthcare will undertake an evaluation to review the results of Cann’s Phase 3 CBD clinical trial, which is currently underway.
The CBD-Satipharm capsule is a potential drug to treat sleep disturbances.
As part of the deal, GSK Consumer Healthcare will pay Cann £100,000 as a non-refundable payment.
Medtech company 4DMedical (ASX:4DX) has kicked off a clinical pilot to trial the first commercial usage of the XV LVAS software in the US.
The pilot program is being conducted at Providence St. Joseph Hospital in Orange County, California.
There, the XV LVAS software is being used to assist in screening for multiple respiratory conditions – including chronic obstructive pulmonary disease (COPD), and long-Covid.
4DMedical says these clinical pilots are an important part of its commercialisation strategy, allowing hospitals to trial the software before purchasing.
“While the US pilot has been slower to get moving than we anticipated, we are excited by the momentum it injects into our commercialisation efforts at this time,” said 4DMedical founder and CEO, Dr Andreas Fouras.
Apart from the US, the company has also taken steps to enter the Australian market, where its 4D respiratory scans are already being used on a commercial basis through the I-MED Radiology Network (I-MED).
The I-MED is the largest provider of medical imaging devices in Australia.
Alcidion (ASX:ALC) has signed another deal with a UK hospital network, this time locking in a five-year deal with the East Lancashire Hospitals NHS Trust.
The deal will see East Lancashire implement the Miya Flow module of Alcidion’s Miya Precision software.
This represents an upgrade to the existing ExtraMed patient flow solution, which has been used at East Lancashire for almost a decade.
The Miya platform allows hospitals to obtain real-time knowledge of bed capacity, gaining early visibility of incoming patients with clinical context.
Total contract value for this five-year deal is expected to be $1.43m over five years.
The deal comes following a previous similar deal with Herefordshire and Worcestershire NHS Trust in March, where Alcidion secured a five-year $1.35m contract.
Polynovo (ASX:PNV) had a record (unaudited) March quarter revenue of $12.26m, up 59.3% on the pcp.
This takes its YTD revenue to $30.42m, which includes income of $1m from BARDA, along with a $0.1m from a Victorian State Government grant.
BARDA is the US Biomedical Advanced Research and Development Authority.
Cash at 31 March excluding any proceeds from the sale of the Lorimer Street property was $3.80m, an increase of $0.5m over cash at 31 December.
Polynovo is the proprietary owner of NovoSorb, a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings.
It’s used as a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burn.